Barbexaclone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Barbexaclone
Barbexaclon Structural Formula V1.svg
Combination of
PhenobarbitalBarbiturate
LevopropylhexedrineStimulant (sympathomimetic)
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ECHA InfoCard100.022.278 Edit this at Wikidata
 ☒N☑Y (what is this?)  (verify)

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[1] It was introduced in 1983. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[2] had not yet been confirmed nor denied in controlled trials.

Potency[edit]

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[1]

References[edit]

  1. ^ a b Simon Shorvon; Emilio Perucca; Jerome Engel, Jr. (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
  2. ^ Salles Barbosa, MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–9. PMID 28716.
Bibliography
  • The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. p. 472. ISBN 0-632-06046-8